Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys

Vaccine

Volumn 22, Issue 25-26, 2004, Pages 3258-3269

  Maggiorella, Maria Teresa ^a   Baroncelli, Silvia ^a   Michelini, Zuleika ^a   Fanales Belasio, Emanuele ^a   Moretti, Sonia ^a   Sernicola, Leonardo ^a   Cara, Andrea ^a   Negri, Donatella R M ^a   Buttò, Stefano ^a   Fiorelli, Valeria ^a   Tripiciano, Antonella ^a   Scoglio, Arianna ^a   Caputo, Antonella ^b   Borsetti, Alessandra ^a   Ridolfi, Barbara ^a   Bona, Roberta ^a   Haaft, Peter Ten ^c   Macchia, Iole ^a   Leone, Pasqualina ^a   Pavone Cossut, Maria Rosaria ^a   Nappi, Filomena ^a   Ciccozzi, Massimo ^a   Heeney, Jonathan ^c   Titti, Fausto ^a   Cafaro, Aurelio ^a   Ensoli, Barbara ^a   more..

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

HIV vaccine; Macaca fascicularis; Tat

Indexed keywords

DNA; GAG PROTEIN; PROTEIN ANTIBODY; TRANSACTIVATOR PROTEIN;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPH NODE; MALE; MONKEY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS REPLICATION;

EID: 4043096335     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.03.009     Document Type: Article

References (69)

1. Arya S.K., Guo C., Josephs S.F., Wong-Staal F. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science. 229(4708):1985;69-73
2. Fisher A.G., Feinberg M.B., Josephs S.F., Harper M.E., Marselle L.M., Reyes G., et al. The trans-activator gene of HTLV-III is essential for virus replication. Nature. 320(6060):1986;367-371
3. Wu Y., Marsh J.W. Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science. 293(5534):2001;1503-1506
4. Sodroski J., Patarca R., Rosen C., Wong-Staal F., Haseltine W. Location of the trans-activating region on the genome of human T-cell lymphotropic virus type III. Science. 229(4708):1985;74-77
5. Cullen B.R., Greene W.C. Regulatory pathways governing HIV-1 replication. Cell. 58(3):1989;423-426
6. Ensoli B., Buonaguro L., Barillari G., Fiorelli V., Gendelman R., Morgan R.A., et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol. 67(1):1993;277-287
7. Chang H.K., Gallo R.C., Ensoli B. Regulation of cellular gene expression and function by the human immunodeficiency virus type 1 Tat protein. J Biomed Sci. 2(3):1995;189-202
8. Ensoli B., Barillari G., Salahuddin S.Z., Gallo R.C., Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature. 345(6270):1990;84-86
9. Chang H.C., Samaniego F., Nair B.C., Buonaguro L., Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS. 11(12):1997;1421-1431
10. Frankel A.D., Pabo C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 55(6):1988;1189-1193
11. Fawell S., Seery J., Daikh Y., Moore C., Chen L.L., Pepinsky B., et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA. 91(2):1994;664-668
12. Huang L., Bosch I., Hofmann W., Sodroski J., Pardee A.B. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. J Virol. 72(11):1998;8952-8960
13. Secchiero P., Zella D., Capitani S., Gallo R.C., Zauli G. Extracellular HIV-1 tat protein up-regulates the expression of surface CXC-chemokine receptor 4 in resting CD4+ T cells. J Immunol. 162(4):1999;2427-2431
14. Weiss J.M., Nath A., Major E.O., Berman J.W. HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes. J Immunol. 163(5):1999;2953-2959
15. de Paulis A., De Palma R., Di Gioia L., Carfora M., Prevete N., Tosi G., et al. Tat protein is an HIV-1-encoded beta-chemokine homolog that promotes migration and up-regulates CCR3 expression on human Fc epsilon RI+ cells. J Immunol. 165(12):2000;7171-7179
16. Viscidi R.P., Mayur K., Lederman H.M., Frankel A.D. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science. 246(4937):1989;1606-1608
17. Subramanyam M., Gutheil W.G., Bachovchin W.W., Huber B.T. Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness. J Immunol. 150(6):1993;2544-2553
18. Ensoli B., Gendelman R., Markham P., Fiorelli V., Colombini S., Raffeld M., et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature. 371(6499):1994;674-680
19. Li C.J., Friedman D.J., Wang C., Metelev V., Pardee A.B. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science. 268(5209):1995;429-431
20. Zagury J.F., Sill A., Blattner W., Lachgar A., Le Buanec H., Richardson M., et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol. 1(4):1998;282-292
21. Barillari G., Sgadari C., Fiorelli V., Samaniego F., Colombini S., Manzari V., et al. The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. Blood. 94(2):1999;663-672
22. Barillari G., Sgadari C., Palladino C., Gendelman R., Caputo A., Morris C.B., et al. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. J Immunol. 163(4):1999;1929-3195
23. Reiss P., Lange J.M., de Ronde A., de Wolf F., Dekker J., Debouck C., et al. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1. J Med Virol. 30(3):1990;163-168
24. Rodman T.C., To S.E., Hashish H., Manchester K. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein. Proc Natl Acad Sci USA. 90(16):1993;7719-7723
25. Re M.C., Furlini G., Vignoli M., Ramazzotti E., Roderigo G., De R.V., et al. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J Acquir Immune Defic Syndr Hum Retrovirol. 10(4):1995;408-416
26. Zagury D., Lachgar A., Chams V., Fall L.S., Bernard J., Zagury J.F., et al. Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc Natl Acad Sci USA. 95(7):1998;3851-3856
27. Re M.C., Vignoli M., Furlini G., Gibellini D., Colangeli V., Vitone F., et al. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. J Clin Virol. 21(1):2001;81-89
28. Buttò S., Fiorelli V., Tripiciano A., Ruiz-Alvarez M.J., Scoglio A., Ensoli F., et al. Cross-recognition of the Clade B HIV-1 Tat protein vaccine candidate by antibodies from HIV-1-infected Italian. Ugandan and South African individuals. J Infect Dis. 188:2003;1171-1180
29. van Baalen C.A., Pontesilli O., Huisman R.C., Geretti A.M., Klein M.R., de Wolf F., et al. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol. 78(Pt 8):1997;1913-1918
30. Addo M.M., Altfeld M., Rosenberg E.S., Eldridge R.L., Philips M.N., Habeeb K., et al. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci USA. 98(4):2001;1781-1786
31. Allen T.M., O'Connor D.H., Jing P., Dzuris J.L., Mothe B.R., Vogel T.U., et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature. 407(6802):2000;386-390
32. Fanales-Belasio E., Moretti S., Nappi F., Barillari G., Micheletti F., Cafaro A., et al. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J Immunol. 168(1):2002;197-206
33. Kim D.T., Mitchell D.J., Brockstedt D.G., Fong L., Nolan G.P., Fathman C.G., et al. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J Immunol. 159(4):1997;1666-1668
34. Cafaro A., Caputo A., Fracasso C., Maggiorella M.T., Goletti D., Baroncelli S., et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med. 5(6):1999;643-650
35. Cafaro A., Caputo A., Maggiorella M.T., Baroncelli S., Fracasso C., Pace M., et al. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. J Med Primatol. 29(3-4):2000;193-208
36. Cafaro A., Titti F., Fracasso C., Maggiorella M.T., Baroncelli S., Caputo A., et al. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine. 19(2022):2001;2862- 2877
37. Caselli E., Betti M., Grossi M.P., Balboni P.G., Rossi C., Boarini C., et al. DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat. J Immunol. 162(9):1999;5631-5638
38. Caputo A., Betti M., Altavilla G., Bonaccorsi A., Boarini C., Marchisio M., et al. Micellar-type complexes of tailor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application. Vaccine. 20(17-18):2002;2303-2317
39. Osterhaus A.D., van Baalen C.A., Gruters R.A., Schutten M., Siebelink C.H., Hulskotte E.G., et al. Vaccination with Rev and Tat against AIDS. Vaccine. 17(20-21):1999;2713-2714
40. Calarota S., Bratt G., Nordlund S., Hinkula J., Leandersson A.C., Sandstrom E., et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet. 351(9112):1998;1320-1325
41. Calarota S.A., Leandersson A.C., Bratt G., Hinkula J., Klinman D.M., Weinhold K.J., et al. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. J Immunol. 163(4):1999;2330-2338
42. Karlsson G.B., Halloran M., Li J., Park I.W., Gomila R., Reimann K.A., et al. Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys. J Virol. 71(6):1997;4218-4225
43. Ten Haaft P., Verstrepen B., Uberla K., Rosenwirth B., Heeney J. A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. J Virol. 72(12):1998;10281-10285
44. Sharkey M.E., Teo I., Greenough T., Sharova N., Luzuriaga K., Sullivan J.L., et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med. 6(1):2000;76-81
45. Cara A., Vargas J. Jr., Keller M., et al. Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA. Virology. 292(1):2002;1-5
46. Titti F., Sernicola L., Geraci A., Panzini G., Di Fabio S., Belli R., et al. Live attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in cynomolgus monkeys. J Gen Virol. 78(Pt 10):1997;2529-2539
47. Heeney J.L. Primate models for AIDS vaccine development. AIDS. 10(Suppl. A):1996;S115-S122
48. Ensoli B, Cafaro A. Novel strategies toward the development of an effective vaccine to prevent human immunodeficiency virus infection or acquired immunodeficiency virus. In: Volberding PA, Jacobson MA, editors. AIDS clinical review 2000/2001. New York: Marcel Dekker; 2001. p. 23-61.
49. Kent S.J., Ada G.L., Hayes E., Lewis I.M. Determining the immune mechanisms of protection from AIDS: correlates of immunity and the development of syngeneic macaques. Immunol Rev. 183(1):2001;94-108
50. Mooij P., Heeney J.L. Rational development of prophylactic HIV vaccines based on structural and regulatory proteins. Vaccine. 20(3-4):2001;304-321
51. Henrard D.R., Phillips J.F., Muenz L.R., Blattner W.A., Wiesner D., Eyster M.E., et al. Natural history of HIV-1 cell-free viremia. JAMA. 274(7):1995;554-558
52. Mellors J.W., Rinaldo C.R. Jr., Gupta P., White R.M., Todd J.A., Kingsley L.A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 272(5265):1996;1167-1170
53. Lifson J.D., Nowak M.A., Goldstein S., Rossio J.L., Kinter A., Vasquez G., et al. The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol. 71(12):1997;9508-9514
54. Watson A., Ranchalis J., Travis B., McClure J., Sutton W., Johnson P.R., et al. Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J Virol. 71(1):1997;284-290
55. Kaufmann G.R., Cunningham P., Zaunders J., Law M., Vizzard J., Carr A., et al. Impact of early HIV-1 RNA and T-lymphocyte dynamics during primary HIV-1 infection on the subsequent course of HIV-1 RNA levels and CD4+ T-lymphocyte counts in the first year of HIV-1 infection. Sydney Primary HIV Infection Study Group. J Acquir Immune Defic Syndr. 22(5):1999;437-444
56. Anastos K., Kalish L.A., Hessol N., Weiser B., Melnick S., Burns D., et al. The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected women: results of the women's interagency HIV study. AIDS. 13(13):1999;1717-1726
57. Lyles C.M., Dorrucci M., Vlahov D., Pezzotti P., Angarano G., Sinicco A., et al. Longitudinal human immunodeficiency virus type 1 load in the italian seroconversion study: correlates and temporal trends of virus load. J Infect Dis. 180(4):1999;1018-1024
58. Staprans S.I., Dailey P.J., Rosenthal A., Horton C., Grant R.M., Lerche N., et al. Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection. J Virol. 73(6):1999;4829-4839
59. Cara A., Reitz M.S. Jr. New insight on the role of extrachromosomal retroviral DNA. Leukemia. 11(9):1997;1395-1399
60. Panther La, Coombs R.W., Zeh J.E., Collier A.C., Corey L. Unintegrated circular HIV-1 DNA in the peripheral mononuclear cells of HIV-1 infected subjects: association with high levels of plasma HIV-1 RNA, rapid decline in CD4 count, and clinical progression to AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. 17(4):1998;303-313
61. Panther L.A., Coombs R.W., Aung S.A., Dela R.C., Gretch D., Corey L. Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro. J Med Virol. 58(2):1999;165-173
62. Rosenberg Y.J., Lewis M.G., Leon E.C., Cafaro A., Eddy G.A., Greenhouse J.J. Viral DNA burden and decline in percentage of CD4 positive cells in the lymphoid compartment of SIV-infected macaques. AIDS Res Hum Retroviruses. 10(10):1994;1269-1277
63. O'Connor D.H., Allen T.M., Vogel T.U., Jing P., DeSouza I.P., Dodds E., et al. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med. 8(5):2002;493-499
64. Yang O.O., Sarkis P.T., Ali A., Harlow J.D., Brander C., Kalams S.A., et al. Determinants of HIV-1 mutational escape from cytotoxic T lymphocytes. J Exp Med. 197(10):2003;1365-1375
65. Gruters R.A., van Baalen C.A., Osterhaus A.D.M.E. The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes. Vaccine. 20(15):2002;2011-2015
66. Hel Z., Tryniszewska E., Tsai W.P., Johnson J.M., Harrod R., Fullen J., et al. Design and in vivo immunogenicity of a polyvalent vaccine based on SIVmac regulatory genes. DNA Cell Biol. 21(9):2002;619-626
67. Allen T.M., Mortara L., Mothe B.R., Liebl M., Jing P., Calore B., et al. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol. 76(8):2002;4108-4112
68. Silvera P., Richardson M.W., Greenhouse J., Yalley-Ogunro J., Shaw N., Mirchandani J., et al. Outcome of Simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein. J Virol. 76(8):2002;3800-3809
69. Pauza C.D., Trivedi P., Wallace M., Ruckwardt T.J., Le Buanec H., Lu W., et al. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Natl Acad Sci USA. 97(7):2000;3515-3519